A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome (clinicaltrials.gov) - Oct 21, 2026 - P3 | N=170 | Active, not recruiting | Sponsor: Stoke Therapeutics, Inc | Recruiting ➔ Active, not recruiting
Enrollment closed • CNS Disorders • Epilepsy
|